RAPID POTENTIOMETRIC DETERMINATION OF CHOLINESTERASES IN PLASMA AND RED-CELLS - APPLICATION TO EPTASTIGMINE MONITORING

被引:5
作者
CAZZOLA, E
LATTUADA, N
ZECCA, L
RADICE, D
LUZZANA, M
IMBIMBO, BP
AUTERI, A
MOSCA, A
机构
[1] UNIV MILAN,DIPARTIMENTO SCI & TECNOL BIOMED,VIA OLGETTINA 60,I-20132 MILAN,ITALY
[2] CNR,IST TECNOL BIOMED AVANZATE,I-20133 MILAN,ITALY
[3] UNIV SIENA,CATTEDRA IMMUNOL CLIN & ALLERG,I-53100 SIENA,ITALY
[4] MEDIOLANUM FARMACEUT,MILAN,ITALY
关键词
ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; DIFFERENTIAL PH; ERYTHROCYTES;
D O I
10.1016/0009-2797(93)90053-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Eptastigmine (MF 201) is a new physostigmine derivative with potent inhibitory activity on cholinesterases. Here we present a new potentiometric cholinesterase activity assay suitable for MF 201 monitoring. The analysis is performed on a differential pH system and has the following characteristics: (a) within-run precision: C.V. 2.0% (plasma cholinesterase), 1.8% (red cell cholinesterase); (b) between-run precision: C.V. 4.0% (plasma cholinesterase); (c) linearity: 1-10 kU/l (plasma cholinesterase), 6-70 U/g Hb (red cell cholinesterase); (d) comparison with a reference method (x, HITACHI 737 Boerhinger Mannheim, Italy): y = 0.785x - 0.07; n = 37; r = 0.998. The assay has been applied to the determination of plasma and red cell cholinesterase activity in volunteers over 60 years of age treated with a single oral dose of 30 mg eptastigmine. We found that red cell cholinesterase is selectively inhibited after MF 201 administration with the following kinetics (time, % of inhibition, mean +/- S.E., n = 6): 0 h, 0; 1 h, 17 +/- 4.6; 2 h, 24 +/- 4; 4 h, 23 +/- 4.4; 12 h, 14 +/- 3. Eptastigmine plasma levels were also determined by a HPLC method: maximum concentration was found one hour after drug administration.
引用
收藏
页码:265 / 268
页数:4
相关论文
共 6 条
[1]  
AUTERI A, 1992, 3RD INT C ALZH DIS R
[2]   MEASUREMENT OF ERYTHROCYTE ACETYLCHOLINESTERASE AND PLASMA CHOLINESTERASE ACTIVITY BY A DIFFERENTIAL PH TECHNIQUE [J].
BARENGHI, L ;
CERIOTTI, F ;
LUZZANA, M ;
RIPAMONTI, M ;
MOSCA, A ;
BONINI, PA .
ANNALS OF CLINICAL BIOCHEMISTRY, 1986, 23 :538-545
[3]   THE EFFECT OF HEPTYL-PHYSOSTIGMINE, A NEW CHOLINESTERASE INHIBITOR, ON THE CENTRAL CHOLINERGIC SYSTEM OF THE RAT [J].
DESARNO, P ;
POMPONI, M ;
GIACOBINI, E ;
TANG, XC ;
WILLIAMS, E .
NEUROCHEMICAL RESEARCH, 1989, 14 (10) :971-977
[4]   NEW ANALOGS OF PHYSOSTIGMINE - ALTERNATIVE DRUGS FOR ALZHEIMERS-DISEASE [J].
MARTA, M ;
CASTELLANO, C ;
OLIVERIO, A ;
PAVONE, F ;
PAGELLA, PG ;
BRUFANI, M ;
POMPONI, M .
LIFE SCIENCES, 1988, 43 (23) :1921-1928
[5]  
MOSCA A, 1990, HAEMATOLOGICA, V75, P397
[6]   KINETICS OF CHOLINESTERASE INHIBITION BY EPTASTIGMINE IN MAN [J].
UNNI, LK ;
HUTT, V ;
IMBIMBO, BP ;
BECKER, RE .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 41 (01) :83-84